報價延遲最少15分鐘:2024/12/23 22:27 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
6.51 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-3.61/-2.72
|
|
企業價值
444.97M
|
| 資產負債 |
|
每股賬面淨值
1.33
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
2.13M
|
|
每股收益
0.03
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2024/12/23 22:27 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease. |